The Heterogeneity of Prostate Cancer

Experts on prostate cancer discuss the heterogeneity of the disease and the rationale for using medications with different mechanisms of action, including androgen deprivation therapy.

EP: 1.Prostate Cancer Treatment: The Evolving Therapeutic Landscape

Now Viewing

EP: 2.The Heterogeneity of Prostate Cancer

EP: 3.The Role of ADT in Localized or Locally Advanced Prostate Cancer

EP: 4.EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

EP: 5.Treatment Considerations in Nonmetastatic CSPC

EP: 6.Combination Therapies and Intensifications of ADT in Advanced Prostate Cancer

EP: 7.Treatment Options in Castration-Resistant Prostate Cancer

EP: 8.The Relationship Between Prostate Cancer and Cardiovascular Disease

EP: 9.Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer

EP: 10.ADT Treatment Considerations and Unmet Needs in Prostate Cancer

Related Videos

Related Content

Advertisement

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.

Related Content

Advertisement

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.